Neurology Clinical Trials Market Size, Share, Trends, Industry Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Value Chain, By Region – Market Forecast, 2025–2034

The global neurology clinical trials market size is expected to reach USD 10.59 billion by 2034, according to a new study by Polaris Market Research. The report “Neurology Clinical Trials Market Size, Share, Trends, Industry Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Value Chain, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The neurology clinical trials market involves the research and development of new drugs, therapies, and medical devices designed to treat conditions of the nervous system. This includes a wide range of diseases and disorders affecting the brain, spinal cord, and peripheral nerves, such as Alzheimer's, Parkinson's, epilepsy, and stroke. The main goal of these trials is to test the safety and effectiveness of new treatments, providing the necessary data for regulatory approval so that new therapies can become available to the public.

The market's growth is largely driven by the increasing number of people worldwide who are affected by neurological disorders, along with clinical trial technology and services. This rising disease burden, combined with the often limited or ineffective treatment options for many conditions, creates a strong demand for new therapies. As a result, there is a lot of research and development happening, supported by growing investments from both private and public sectors. The market's overview shows that it is a complex and competitive field, with a focus on both traditional drug development and newer, more specialized treatments like gene therapies and personalized medicine.

Neurology Clinical Trials Market Report Highlights:

By phase, the phase III segment held the largest share of the neurology clinical trials market in 2024 as these trials are the final and most extensive step before a drug can be submitted for regulatory approval.

By study design, the interventional studies segment held the largest share in 2024. This is due to the fact that these trials are the standard method for testing new drugs and medical devices, as they involve giving a specific treatment to participants and directly measuring its effects.

By indication, the Alzheimer's disease segment held the largest share in 2024. This is because of the large number of people affected by this condition and the urgent global need for effective treatments.

By value chain, the in-house segment held the largest share in 2024 of the market. Many large pharmaceutical and biotech companies have the internal resources, expertise, and funding to manage their entire clinical trial process themselves, giving them full control and ensuring the quality of their research.

By region, North America held the largest share of the neurology clinical trials market in 2024. This is due to its well-developed healthcare system, a high concentration of key pharmaceutical and biotechnology companies, and a significant amount of research and development funding for neurological disorders. The Asia Pacific is a rapidly growing market for neurology clinical trials. The region's growth is driven by its large and diverse patient population, which makes patient recruitment for trials more efficient and cost-effective.

A few key players in the market include IQVIA, ICON plc, Syneos Health, Laboratory Corporation of America Holdings, Charles River Laboratories, Thermo Fisher Scientific, Parexel, Medpace Holdings, and pharmaceutical companies like Pfizer, Biogen, and Eisai Co.

Polaris Market Research has segmented the neurology clinical trials market report based on phase, study design, indication, value chain, and region:

By Phase Outlook (Revenue – USD Billion, 2020–2034)

Phase I

Phase II

Phase III

Phase IV

By Study Design Outlook (Revenue – USD Billion, 2020–2034)

Interventional

Observational

Expanded Access

By Indication Outlook (Revenue – USD Billion, 2020–2034)

Alzheimer’s Disease

Depression (MDD)

Parkinson's Disease (PD)

Epilepsy

Stroke

Traumatic Brain Injury (TBI)

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Muscle Regeneration

Others

By Value Chain Outlook (Revenue – USD Billion, 2020–2034)

In-house

CROs

Investigator Sites/Clinical Sites

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more